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A NEW MODEL TO STUDY THE EFFECTS OF ADVANCED GLYCATION
ENDPRODUCTS ON THE PROGRESSION OF SPONTANEOUS
OSTEOARTHRITIS
T.L. Willett1,2, A. Decroos1, N. Avery3, R. Kandel1,2, M. Grynpas1,2. 1Mount
Sinai Hosp., Toronto, ON, Canada; 2Univ. of Toronto, Toronto, ON, Canada;
3Univ. of Bristol, Bristol, United Kingdom
Purpose: To determine if advanced glycation endproducts (AGEs)
alter the extent of spontaneous osteoarthritis (OA) progression in the
male Hartley Guinea Pig (HGP). Some investigators hypothesize that
accumulation of AGEs (due to ageing or disease) may play a role in
OA pathogenesis by various mechanisms (biochemical, biomechanical).
DeGroot et al. (Arth. & Rheum, 2004) reported that a 5-fold increase
in AGE content of articular cartilage due to intra-articular injections
of PBS containing ribose lead to greater osteoarthritis in a dog ACL
injury model of secondary OA. However, that study did not address the
possibly more insidious role AGEs may play in primary, idiopathic OA
development. Therefore, we determined to study the effect in HGPs –
the gold standard model for spontaneous OA.
Methods: Fifteen male retired-breeder (~1 year) HGPs received 100ml
intra-articular injections in the right knee [PBS (n =5), PBS+0.6M ribose
(n =5) or PBS+2.0M ribose (n =5)] once a week for four weeks. Contra-
lateral (left) knees acted as controls. Femoral cartilage and menisci were
harvested for biochemical assays and proximal tibiae were processed for
histological grading using Safranin-O staining and histological scoring
based on the scheme of Kraus et al (Osteoarthritis & Cartilage, 2010).
HPLC was used to quantify pentosidine concentration, an established AGE
biomarker, to quantify the extent of AGE accumulation in the cartilage.
Subsequently, in a long-term study allowing for signiﬁcant OA
progression in HGP knees, twenty male 3-month old HGPs received
intra-articular injections in the right knee [PBS (n =10), PBS+0.6M ribose
(n =10); left knees were controls] for twenty-four weeks (9 months
old). Additionally, four non-injected controls HGPs were euthanized at
3-months and another four at the end of the experiment. The tissues
were harvested and prepared as discribed above.
Results: In the ﬁrst study, increased pentosidine content was detected
in the menisci of the 0.6M and 2.0M ribose groups compared to
the PBS controls. A dose response was conﬁrmed and pentosidine
levels reached those of mature human cartilage in the 2.0M
treated group (3.5±1.0mmol pentosidine per mol collagen versus
0.63±0.17mmol pentosidine per mol collagen in control menisci).
Histological examination of the tibial plateau conﬁrmed no acute reaction
to the injections and did not demonstrate a difference in disease state
between the groups (Kraus score ~16±2), likely because the disease had
already progressed signiﬁcantly in the retired breeders by the start of the
study. During the 24-week study, the ribose injected group unexpectedly
gained less mass, ranging between 6–8% less between weeks 12 and
24. This suggests that the ribose treated group may have experienced
greater pain/inﬂammation. 0.6M ribose allows for a slower accumulation
of AGEs during the treatment period so that levels remain physiological
but reach levels similar to 80-year old human cartilage (approx. 8mmol
pentosidine per mol collagen) by 24 weeks. During the period of 3 to
9 months of age, OA typically develops to a moderate level in this model
(Kraus score increasing from less than 2 to 12).
Conclusions: An in vivo model to test the effect of AGEs on the gradual
progression of idiopathic knee osteoarthritis has been established. AGE
content reaches levels found in aged cartilage.
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INCREASED CARTILAGE DAMAGE IN PAPAIN- AND
COLLAGENASE-INDUCED OSTEOARTHRITIS IN LRP5−/− MICE WITH
LOW BONE MASS DENSITY
L. Lodewyckx, F.P. Luyten, R.J. Lories. KULeuven, Leuven, Belgium
Purpose: Low-density lipoprotein receptor-related protein 5 (LRP5)
is a WNT co-receptor, important in the canonical WNT signaling
pathway and with a critical role in bone homeostasis. Mutations in
the human LRP5 gene are the cause of osteoporosis-pseudoglyoma
syndrome (OPPG) characterised by severe juvenile onset osteoporosis.
Gain-of-function mutations on the other hand result in abnormally
high bone density disorders. Recently, an osteoarthritis susceptibility
locus was found on chromosome 11q12–13, including the LRP5 gene
and a signiﬁcantly higher osteophyte formation score was found in
postmenopausal Japanese women carrying a LRP5 low bone density
polymorphism. We used the Lrp5−/− mice, in two mouse models of
osteoarthritis.
Methods: Osteoarthritis was induced in male wild-type or Lrp5−/−mice
at 8 weeks of age by intra-articular injection in the right knee of 10ml
of 2 U/ml collagenase type VII or 10ml of 1% papain/0.03M L-cystein.
The left knee was injected with 10ml PBS as a negative control. 11 and
9 mice/group were induced for the papain- and collagenase-induced
osteoarthritis model respectively. After 7 days mice were sacriﬁced
and knees were isolated for histology. Knee sections were stained with
haematoxylin-eosin and safranin O and severity of arthritis was scored.
Results: Both papain- and collagenase-induced osteoarthritis resulted in
increased cartilage damage in Lrp5−/−mice as compared to the wild-type
mice. Inﬂammation scores (inﬁltration, hyperplasia and ﬁbrosis) were
also signiﬁcantly higher in collagenase-induced Lrp5−/−mice, but not in
the papain-induced osteoarthritis model.
Conclusions: In this study we show that Lrp5−/− mice, characterised by
low bone mass density, are more susceptible to cartilage degradation
induced by papain- and collagenase-induced osteoarthritis. These effects
could be caused by either loss of WNT signaling in the joint or by
changes in the bone-cartilage biomechanical unit secondary to the low
bone mass in Lrp5−/−mice.
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CHARACTERISATION OF TEMPORAL SUBCHONDRAL BONE CHANGES
IN A RAT MODEL OF LOW-DOSE MONOSODIUM IODOACETATE
INDUCED OSTEOARTHRITIS: AN IN VIVO MICRO-CT STUDY
G. Mohan1,2, E. Perilli1,2, J. Kuliwaba1,2, I. Parkinson1,2, J. Humphries1,2,
N. Fazzalari1,2. 1Bone and Joint Res. Lab., Surgical Pathology, SA Pathology
and Hanson Inst., Adelaide, SA, Australia; 2Discipline of Anatomy and
Pathology, Sch. of Med. Sci., The Univ. of Adelaide, Adelaide, SA, Australia
Purpose: Animal models of osteoarthritis (OA) are important tools
to understand the pathology of OA. Moreover, knowledge of early
pathological changes is essential for early treatment options and to
develop better therapeutic agents to modify the disease progression.
Although OA involves the whole joint, there is increasing evidence that
changes in the subchondral trabecular bone are also an underlying cause.
The purpose of this study was to perform a comprehensive longitudinal in
vivo characterisation of a rat model of low-dose monosodium iodoacetate
(MIA)-induced OA that closely mimics progressive human OA, using non-
invasive in vivo micro-CT imaging.
Methods: Twelve young adult male Wistar rats (200–230g) received
a single intra-articular injection of 0.2mg MIA in the right knee joint
and sterile saline in the left knee joint. The animals were scanned in
vivo by micro-CT (Skyscan 1076, Skyscan, Kontich, Belgium) at 2, 6, and
10 weeks post-injection, analogous to early, intermediate, and advanced
stages of OA, to assess architectural changes in the tibial subchondral
trabecular bone. An incapacitance tester was used to determine changes
in hind paw weight distribution at day −1, 1, 3, 5, 7, 9, 12, and 14 post-
injection, as an index of joint discomfort in the OA knee. A blood sample
was collected at 2, 6, and 10 weeks, from each animal to measure the
serum bone turnover marker C-terminal telopeptide of type I collagen
(CTX-I), and the cartilage turnover marker cartilage oligomeric matrix
protein (COMP). The articular cartilage changes in the tibia were assessed
macroscopically and histologically at 10 weeks post-injection.
Results: Micro-CT analysis of tibial subchondral trabecular bone in the
MIA-injected knee showed signiﬁcant bone loss at 2 weeks (p = 0.032
for bone volume fraction). This was followed by an increase in bone
volume associated with signiﬁcantly increased trabecular thickness and
separation at 6 weeks (p < 0.001, p = 0.001, respectively) and 10 weeks
(p = 0.002, p = 0.001, respectively); whereas trabecular number was
decreased at all time points compared to control tibiae (p = 0.009,
p = 0.012 at 2 and 10 weeks respectively). At 10 weeks, histology revealed
chondrocyte necrosis, chondrocyte clusters, cartilage ﬁbrillation, and
delamination (Fig. 1). The OARSI score of the medial tibial plateau of
the MIA-injected knee at 10 weeks was 17±3 (mean ± SD). Subchondral
trabecular bone sclerosis, cysts, osteophytes (Fig. 2) and subchondral
plate breach were observed in the tibia of the MIA injected knee at
10 weeks. The control tibiae showed no OA-like changes.
The weight distribution on the right limb was signiﬁcantly reduced on
days 1, 3, and 5 compared to baseline (p < 0.05, p < 0.001, and p < 0.05,
respectively). From day 7, the weight distribution returned to normal. The
serum CTX-I, and COMP levels showed signiﬁcant negative correlation
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with histomorphometric parameters such as bone volume fraction
(r = −0.89, p < 0.0001; r = −0.5, p < 0.007; respectively) and trabecular
number (r = −0.71, p < 0.0001; r = −0.38, p < 0.037; respectively).
Fig. 1. Coronal section of medial tibial plateau of saline injected knee (A).
The MIA-injected knee (B–D) shows loss of proteoglycan, chondrocyte
proliferation (B, arrow), chondrocyte cluster (B, arrow head), ﬁbrillation
(C, arrow), delamination, subchondral bone sclerosis, and ﬁbrotic bone
marrow (D, arrow).
Fig. 2. Coronal micro-CT images show osteophytes (A, arrow) and
cysts (C, asterisk) in the medial tibia of MIA-injected knee. Histology
sections conﬁrmed osteophyte (B, arrow) and cyst (D, asterisk) formation.
Note the presence of osteoblasts lining the areas of bone resorption
(D, arrow).
Conclusions: These ﬁndings demonstrate that the low-dose MIA rat
model closely mimics the pathological features of progressive human
OA such as cartilage degradation, subchondral bone sclerosis, cyst and
osteophyte formation. Moreover, this model demonstrates measurable
changes in both the cartilage and the subchondral bone. Monitoring
of low-dose MIA induced OA in rats using in vivo micro-CT enables
tracking of structural changes in the tibial subchondral bone for the
individual animal over time, and could be used to track changes in bone
in preclinical drug intervention studies for treatment of OA.
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PREMATURE OSTEOARTHRITIS IN THE TEMPOROMANDIBULAR AND
KNEE JOINTS OF BARDET-BIEDLE SYNDROME MICE
D.M. Peterson1, D. Weipert1, K.W. Airmet1, S. Killingsworth1, M.R. Klein1,
T.D. Beardsley1, L.C. Bridgewater1, R.E. Seegmiller1,2, J.A. Morcuende3,
D.L. Kooyman1, V.C. Shefﬁeld3. 1Brigham Young Univ., Provo, UT, USA;
2Roseman Univ. Sch. of Dentistry, South Jordan, UT, USA; 3Univ. of Iowa,
Iowa City, IA, USA
Purpose: A homozygous recessive disorder in humans called Bardet-
Biedl Syndrome (BBS) results in primary cilia defects. BBS mutant
mice similarly exhibit ciliopathy related disorders. Chondrocytes are
known to contain primary cilia. Primary cilia have been shown to
play fundamental cellular roles. In the present study we analyzed the
temporomandibular (TM) and knee joints of BBS mutant mice as a
normal collagen chondrocyte speciﬁc animal model of osteoarthritis (OA)
in humans.
Methods: BBS mutant mice, and age-matched controls, were compared
histologically at 3, 6 and 12 months of age. Tissues were ﬁxed in
4% paraformaldehyde, processed to parafﬁn sections, stained with
Hemotoxylin, Safranin O and Fast Green, and analyzed using light
microscopy. Joint morphology was characterized and compared using
ImageJ (NIH; Bethesda, MD). Sections were stained for HtrA1 and DDR2.
Results: BBS mutant mice demonstrated evidence of OA including
articular cartilage (AC) ﬁssuring, thinning, decrease in proteoglycan
saturation with a concomitant increase in HtrA1 and DDR2. Chondrocytes
exhibited a propensity for clustering within the matrix. The extent of OA
related abnormalities was more pronounced in TM versus knee joints.
Conclusions: These results suggest a mechanism of early onset OA in TMJ
and knees of BBS mutant mice. The degradation pattern of the articular
cartilage, including up regulation of HtrA1 and DDR2, in the TMJ and
knees of BBS mutant mice follows the same recognized process that has
been observed in mutant collagen OA mouse models. The exacerbated
condition of the TMJ compared to knee might indicate that TMJ AC is
unique. The present study shows the relevance of the BBS homozygous
mouse as a viable alternative model for the human condition of OA.
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CARTILAGE AND BONE DISEASE IN RATS WITH
MUCOPOLYSACCHARIDOSIS TYPE VI (MAROTEAUX-LAMY DISEASE):
A NEW, NATURALLY OCCURRING ANIMAL MODEL OF ARTHRITIS
E.H. Schuchman, Y. Ge, E. Eliyahu, K. Jepsen, C. Simonaro. Mount Sinai
Sch. of Med., NY, NY, USA
Background & Purpose: The mucopolysaccharidoses (MPS) are a group of
11 distinct inherited disorders due to mutations in the genes encoding
enzymes of glycosaminoglycan (GAG) degradation. Progressive and
severe bone and cartilage pathology are characteristic of these disorders.
Naturally occurring animal models have been described for several MPS,
with similarly severe cartilage and bone disease. The goal of this study
was to determine the inﬂammatory and cartilage/bone changes in the
rat model of MPS type VI (Maroteaux-Lamy disease), and to study of the
effects of anti-TNF-alpha drugs on the disease progression.
Methods: The age-progressive cartilage and bone disease in MPS VI
and control rats were studied by a variety of standard biochemical,
histological and clinical methods. MPS VI rats also were treated with the
anti-TNF-alpha drug, CTNO1081, and the effects on cartilage and bone
disease evaluated.
Results: The pathological and biochemical changes in the MPS VI
rats were very similar to those reported previously in patients
with arthritis and induced animal models of the disease. These
included elevation of various inﬂammatory markers, including TNF-
alpha, enhanced chondrocyte apoptosis, synovial hyperplasia, and
proteoglycan degradation. We therefore treated these animals with the
experimental anti-TNF-alpha drug, CTNO181. When initiated at 1 month
of age, intravenous treatment with CNTO1081 prevented the elevation
of TNF-alpha, RANKL and other inﬂammatory molecules, not only in the
blood, but also in articular chondrocytes and ﬁbroblast-like synoviocytes
(FLS). Treatment of 6 month-old animals also reduced the levels of these
molecules to normal. The number of apoptotic articular chondrocytes
in MPS VI rats was similarly reduced, with less inﬁltration of synovial
tissue into the underlying bone.
Conclusions: Many of the inﬂammatory and cartilage/chondrocyte
pathological changes that occurred in the MPS VI rats resembled those
